Lataa...
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned...
Tallennettuna:
| Julkaisussa: | Pulm Circ |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467933/ https://ncbi.nlm.nih.gov/pubmed/28597752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217702401 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|